A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression

Keyphrases

• Genomic Landscape 100%
• Target Gene Expression 100%
• C-Myc Inhibitor 100%
• Cistrome 100%
• Multiple Genes 33%
• Tumorigenesis 33%
• Breast Cancer Cells 33%
• Combination Therapy 33%
• Family Protein 33%
• Epigenome 33%
• Signal Transduction Pathway 33%
• Prostate Cancer Cells 33%
• Estrogen 33%
• Small Molecules 33%
• 4-hydroxytamoxifen 33%
• Cancer Therapeutics 33%
• Gene Targeting 33%
• Transcriptome 33%
• Resistant Prostate Cancer 33%
• Pathway Genes 33%
• Forkhead Box A1 (FOXA1) 33%
• Enzalutamide 33%
• Chromatin Accessibility 33%
• H3K27 Acetylation 33%
• Chromatin Binding 33%
• Transcriptional Pathways 33%
• Gene Programs 33%
• Forkhead Box M1 (FOXM1) 33%
• MiRNA Biogenesis 33%
• MYC Target Genes 33%
• Protein Availability 33%
• AR-V7 33%

Biochemistry, Genetics and Molecular Biology

• Cancer Cell 100%
• Gene Expression 100%
• Epigenome 50%
• Carcinogenesis 50%
• Small Molecule 50%
• Cell Cycle 50%
• Signal Transduction 50%
• RNA 50%
• Protein Family 50%
• Biogenesis 50%
• Acetylation 50%
• FOXA1 50%
• FOXM1 50%
• Enzalutamide 50%
• Transcriptome 50%
• Chromatin Accessibility 50%